Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

301.32USD
26 Mar 2015
Change (% chg)

$0.69 (+0.23%)
Prev Close
$300.63
Open
$298.00
Day's High
$305.22
Day's Low
$297.20
Volume
607,816
Avg. Vol
597,067
52-wk High
$317.72
52-wk Low
$184.94

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $122,034.60
Shares Outstanding(Mil.): 405.00
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 40.43 40.89
EPS (TTM): -6.09 -- --
ROI: -4.87 16.62 15.96
ROE: -8.61 17.16 16.81
Search Stocks

EU mergers and takeovers (March 17)

BRUSSELS, March 17 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

17 Mar 2015

BRIEF-American Airlines to join S&P 500

March 16 - * S&P Dow jones indices says American Airlines Group Inc to replace

17 Mar 2015

Eli Lilly loses Alimta drug patent case in Germany to Actavis

- Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

06 Mar 2015

UPDATE 1-Eli Lilly loses Alimta drug patent case in Germany to Actavis

March 6 - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

06 Mar 2015

Eli Lilly loses Alimta drug patent case in Germany to Actavis

March 6 - Eli Lilly said on Friday it had lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

06 Mar 2015

EU mergers and takeovers (March 5)

BRUSSELS, March 5 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

05 Mar 2015

BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia

March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and

05 Mar 2015

TREASURIES-Bond prices slip on corporate supply; U.S. data eyed

* Traders await monthly U.S. jobs report (New throughout, updates prices, adds comments)

04 Mar 2015

TREASURIES-Bond prices flat on corporate supply, U.S. debt demand

NEW YORK, March 3 - U.S. Treasuries prices were mostly flat on Tuesday, pressured by corporate bond sales and supported by demand for relatively high U.S. yields, while traders also awaited Friday's U.S. jobs report.

03 Mar 2015

BRIEF-AstraZeneca completes buy of Actavis' portfolio in North America

* Completed transaction to acquire rights to actavis' branded respiratory business in us and canada. Source text for Eikon: Further company coverage:

03 Mar 2015

Earnings vs. Estimates

Search Stocks